Exenatide: Improves glycemic control in patients with type 2 diabetes mellitus

Advances in Pharmacy

Volumn 3, Issue 1, 2005, Pages 14-22

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CORTICOSTEROID; EXENDIN 4; GASTROINTESTINAL HORMONE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONSTIPATION; DIAPHORESIS; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN BLOOD LEVEL; MUSCLE WEAKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 18044383126     PISSN: 15323862     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. National Center for Chronic Disease Prevention and Health Promotion: Diabetes Public Health Resource. Center for Disease Control and Prevention. United States Department of Health and Human Services. Available at: http://www.cdc.gov/diabetes. Accessed on November 20, 2004.
2. Bloomgarden ZT. Pharmacologic treatment of type 2 diabetes. Diabetes Care. 2003;26(2):526-533.
3. Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord. 2002;2(1):63-82.
4. Ruggles JA, Kelemen D, Baron A. Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration. Endocrinol Metab Clin North Am. 2004;33(1):239-252.
5. New drug application for exenatide submitted to FDA for type 2 diabetes. PRNewswire. June 30, 2004 Available at: www.prnewswire.com. Accessed on June 30, 2004.
6. Edwards CM. GLP-1: Target for a new class of antidiabetic agents? J R Soc Med. 2004;97(6):270-274.
7. Hudson FM, Andersen NH. Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state. Biopolymers. 2004;76(4):298-308.
8. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem. 2003;10(22):2471-2483.
9. Giannoukakis N. Exenatide. Curr Opin Investig Drugs. 2003;4(4):459-465.
10. Drucker DJ. Glucagon-like peptides. Diabetes 1998;47:159-69.
11. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50(5):583-589.
12. Drucker DJ. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharma Des. 2001;7(14):1399-1412.
13. Nikoulina S, Gedulin B, Gedulin G, Putvinski S, Young A, Baron A, Parkes D. Exenatide (synthetic exendin-4) modulates beta cell mass in insulin resistant obsess falfa rats [abstract]. Acta Diabetol. 2003;46(75 suppl 2):A29.
14. Alcàntara AI, Morales M, Delgado E, et al. Exendin-4 agonist and exendin(9-39)amine antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys. 1997;341:1-7.
15. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol. 2003;469(1-3):195-200.
16. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Discord. 2003;27(3):313-318.
17. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Acta Diabetol. 2002;45:1410-1415.
18. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem. 2003;278(1):471-478.
19. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 2000;141(6):1936-1941.
20. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:E155-E161.
21. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
22. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second- phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care. 2003;26:791-798.
23. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab. 2003;284:E1072-E1079.
24. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004;53(9):2397-2403.
25. Mack CM, Wilson JK, Young AA, Parkes DG. Effect of systemic 28-day exposure to exenatide (synthetic exendin-4) on food intake and body weight in high fat-fed rats [abstract]. Diabetes. 2004;53(suppl 2):A409.
26. Fehse FC, Trautmann ME, Hoist JJ, et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [abstract]. Diabetes. 2004;53(suppl 2):A82.
27. Kwon G, Marshall CA, Papan KL, Remedi MS, McDaniel ML. Exenatide enhances glucose-dependent activation of mTOR by pancreatic islets [abstract]. Diabetes. 2004;53(suppl 2):A81.
28. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2003;4(4):401-405.
29. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
30. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004;89(7):3469-3473.
31. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87(3):1282-1290.
32. Doyle ME, Theodorakis MJ, Holloway HW, et al. The importance of the nine-ammo acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003;114(2-3):153-158.
33. Calara F, Taylor K, Han J, Aisporna M, et al. Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4) [abstract PII-25]. Clin Pharmacol Ther. 2004;75(2):P58.
34. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26(8):2370-2377.
35. Parkes DG, Jodka C, Smith P, et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res. 2001;53:260-267.
36. Kolterman O, Young G, Parket J, Amin D, Prickett K. Stimulation of endogenous insulin secretion by subcutaneous AC-2993 (synthetic exendin-4) in healthy overnight fasted volunteers [abstract]. Diabetes. 1999;48(suppl 1):A199.
37. Fineman M, Shen L, Smitzi J, et al. Unique study design: Evaluation of the effect of dose titration on dose-limiting nausea [abstract]. Clin Pharmacol Ther. 2002;71:P19.
38. Fineman M, Young A, Gaines E, Prickett K. Dose-response for post-prandial glucose-lowering effect of synthetic exendin-4 (AC-2993) in subjects with type 2 diabetes [abstract]. Diabetes. 2000;49(suppl 1):A106.
39. Phillips L, Fineman M, Taylor K, et al. Population modeling to guide phase 3 dose selection for AC-2993 (synthetic exendin-4) [abstract]. Clin Pharmacol Ther. 2002;71:MPI-96.
40. Taylor K, Kimi D, Bicsak T, et al. Continuous subcutaneous infusion of AC-2993 (synthetic exendin-4) provides sustained day-long glycemic control to patients with type 2 diabetes [abstract]. Diabetes. 2002;51(suppl 2):A85.
41. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411-417.
42. Poon TH, Nelson P, Love K, et al. Twenty-eight day dose-response study with exenatide (synthetic exendin-4) in subjects with type 2 diabetes treated with metformin or with diet and exercise [abstract]. Diabetes. 2004;53(suppl 2):A142.
43. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
44. Defronzo R, Ratner R, Han J, et al. Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [abstract 6-LB]. Presented at: American Diabetes Association Annual Meeting; June 2-8, 2004; Orlando, FL.
45. Kendall DM, Riddle MC, Zhuang D, et al. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea [abstract 352-OR]. Presented at: American Diabetes Association Annual Meeting; June 2-8, 2004; Orlando, FL.
46. Hiles R, Carpenter T, Serota D, et al. Exenatide does not cause pancreatic islet cell proliferative lesions in rats and mice following 2-year exposure [abstract]. Diabetes. 2004;53(suppl 2):A380.